AstraZeneca invests $2 billion in Summit Therapeutics
AstraZeneca announced a $2 billion equity investment and clinical collaboration with Summit Therapeutics to advance cancer therapies.
AstraZeneca announced on September 29, 2026, a strategic equity investment and clinical collaboration with Summit Therapeutics. The company is investing $2 billion in newly issued equity in Summit Therapeutics.
The collaboration aims to advance combination therapies for cancer patients. The clinical trial will evaluate Summit's Claudin-18.2 ADC, sonesitatug vedotin, in combination with AstraZeneca's ivonescimab, a first-in-class PD-1/VEGF bispecific antibody. Treatments will be studied specifically for gastrointestinal cancers.
The broader clinical collaboration will incorporate AstraZeneca's portfolio of cancer medicines, including ADCs, in combination with ivonescimab. This expansion aims to offer new treatment options for a wider range of cancers.